These observations show that the mutation of Spry4 identified in Kallmann syndrome is not affecting the inhibitory potency of the protein on EGF-mediated MAPK activation, suggesting that the effect might be FGF specific. The gene discussed is SPRY4; the disease is Kallmann syndrome.